Roche and Freenome signed a collaboration that could exceed $200 million, including a $75 million Roche equity investment, giving Roche exclusive ex‑US rights to develop distributed, kit‑based versions of Freenome’s blood‑based cancer screening tests. Freenome retains US rights and centralized testing options outside the US. The agreement also contemplates milestones and royalties on ex‑US sales. Roche will contribute kit development capabilities and access to sample cohorts and sequencing‑by‑expansion (SBX) technology to accelerate Freenome’s multi‑cancer screening efforts. Both companies emphasized the potential to scale early detection globally by combining Freenome’s cfDNA assays with Roche’s commercial footprint and diagnostic platforms.